Meaningful Responses With Olaparib and Durvalumab in DDR-Mutated Pancreatic Cancer

ContributorsProf. Dr. Mustafa ÖzdoğanAuthor · Medical review · Editorial approval

PublishedJan 12, 2026

UpdatedOct 17, 2026

4 min read

Meaningful Responses With Olaparib and Durvalumab in DDR-Mutated Pancreatic Cancer

In this article

Targeting Treatment-Resistant Pancreatic Tumors With Olaparib and Durvalumab

Is a New Door Opening in Treatment?

Pancreatic cancer is one of oncology’s toughest strongholds. Particularly in metastatic disease, resistance and progression after some time remain unfortunately common even in patients who respond to standard platinum-based chemotherapy. At this stage, our options are very limited.

A new Phase 2 study presented at the ASCO Gastrointestinal Cancers Symposium 2026 (Abstract 724), however, heralds an exciting development for patients with a specific genetic feature: DDR mutations.

The study shows that combining a drug that disrupts the tumor’s “genetic repair mechanism” (a PARP inhibitor) with one that strengthens the immune system (immunotherapy) can control disease for a long time, even in heavily pretreated patients. Here are the details...

Clinical Glossary: Understanding the Terms

DDR (DNA Damage Repair) Genes: Genes that repair DNA damage in cells (e.g., BRCA1, BRCA2, PALB2). If these genes are defective (mutated), cancer cells cannot repair DNA damage and become vulnerable to PARP inhibitors.

Olaparib (PARP Inhibitor): A targeted drug taken as a pill that also shuts down the cancer cell’s alternative DNA repair pathway, leading to cell death.

Durvalumab (Immunotherapy): An intravenous drug known as a PD-L1 inhibitor that releases the immune system’s brakes, enabling it to attack the tumor.

Synergy: When two drugs together produce much more than their individual effects (1+1 > 2). In this study, the aim was for the PARP inhibitor to make the tumor sensitive to immunotherapy, creating synergy.

Study Design: Who Was Enrolled?

This Phase 2 study, led by Dr. Teresa Macarulla of Spain’s Vall d’Hebron Institute, enrolled patients with metastatic pancreatic cancer: 40 patients whose shared features were:

Genetic Profile: All carried mutations in BRCA1, BRCA2 or PALB2 genes (80% had a BRCA2 mutation).
Treatment History: They had previously received and responded to platinum-based chemotherapy (their tumors had shrunk). However, 82.5% had received at least 3 treatment lines, meaning their options were exhausted.
Administration: Patients received Olaparib (oral pills twice daily) together with Durvalumab (intravenously every 4 weeks).

Results: Success Beyond Expectations

Researchers were cautious because they knew immunotherapy (Durvalumab) alone is not very effective in pancreatic cancer. The results, however, were surprisingly positive.

Tumor Shrinkage Rate (ORR)

%32.5

Tumors shrank substantially in approximately a third of patients. Disease Control Rate (including patients whose tumors did not grow) reached a very high %77.5 level overall.

Survival Statistics

15.4 Months

Median Overall Survival

14.5 Months

Duration of Response

*Survival of 15 months is highly impressive for heavily pretreated metastatic pancreatic cancer.

Side Effects: Is It Tolerable?

The combination was generally found to be safe. Serious treatment-related side effects (Grade 3 or higher) occurred in only 15% of patients.

Anemia (Low red blood cell count): The most common serious side effect (10%).
Manageability: Most side effects were manageable and did not require treatment discontinuation.

DROZDOGAN Academy Commentary

We may have found in PARP inhibitors the key to “immunotherapy sensitivity” that we have sought in pancreatic cancer for years. This study suggests that a chemotherapy-free period, as maintenance treatment, may be possible in patients with DDR mutations (BRCA, etc.).

As Dr. Macarulla noted, results exceeded expectations. Larger Phase 3 trials are needed before this treatment becomes standard. Nevertheless, this regimen may already be a valuable “off-label” or clinical trial option for patients with positive genetic tests who have exhausted their options.

The study once again emphasizes the vital importance of “Genetic Testing” (BRCA, PALB2, etc.) in every patient diagnosed with pancreatic cancer.

Source:

Macarulla T, et al. Durvalumab plus olaparib in patients with metastatic pancreatic cancer and DNA damage repair gene alterations: A phase 2 study. ASCO Gastrointestinal Cancers Symposium. 2026; Abstract 724.

Reader comments

Share your comment

Your name and comment are published only after administrator approval. Your email address is never shown to visitors.

Be the first to comment.

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

Menu

Meaningful Responses With Olaparib and Durvalumab in DDR-Mutated Pancreatic Cancer